

David Cibula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/664012/publications.pdf>

Version: 2024-02-01

267
papers

13,627
citations

23567

58
h-index

27406

106
g-index

289
all docs

289
docs citations

289
times ranked

11491
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative staging of ovarian cancer: comparison between ultrasound, <sc>CT</sc> and whole-body diffusion-weighted <sc>MRI</sc> (<sc>ISAAC</sc> study). Ultrasound in Obstetrics and Gynecology, 2022, 59, 248-262.	1.7	11
2	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. American Journal of Obstetrics and Gynecology, 2022, 226, 97.e1-97.e16.	1.3	20
3	Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study. Gynecologic Oncology, 2022, 164, 76-84.	1.4	3
4	Quality of training in cervical cancer radical surgery: a survey from the European Network of Young Gynaecologic Oncologists (ENYGO). International Journal of Gynecological Cancer, 2022, 32, 494-501.	2.5	5
5	Yolk Sac Tumor of the Omentum: A Case Report and Literature Review. Diagnostics, 2022, 12, 304.	2.6	2
6	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. , 2022, 10, e003190.		16
7	Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic Oncology, 2022, 164, 498-504.	1.4	24
8	SUCCOR cone study: conization before radical hysterectomy. International Journal of Gynecological Cancer, 2022, 32, 117-124.	2.5	36
9	Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis. Gynecologic Oncology, 2022, 164, 446-454.	1.4	22
10	The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nature Communications, 2022, 13, 448.	12.8	20
11	Post-recurrence survival in patients with cervical cancer. Gynecologic Oncology, 2022, 164, 362-369.	1.4	11
12	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nature Communications, 2022, 13, 449.	12.8	21
13	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	7.4	13
14	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	2.5	0
15	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biology, 2022, 23, 52.	8.8	8
16	Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery. Gynecologic Oncology, 2022, , .	1.4	6
17	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 465-478.	10.7	70
18	Ten years of live surgical broadcast at Charit-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003173.	2.5	2

#	ARTICLE	IF	CITATIONS
19	SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4819-4829.	1.5	6
20	Quality of life after extended pelvic exenterations. <i>Gynecologic Oncology</i> , 2022, 166, 100-107.	1.4	6
21	KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5623-TPS5623.	1.6	8
22	Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5519-5519.	1.6	4
23	Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 143, 88-100.	2.8	27
24	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE). <i>Cancer Medicine</i> , 2021, 10, 208-219.	2.8	69
25	Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery. <i>British Journal of Cancer</i> , 2021, 124, 1121-1129.	6.4	7
26	A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma. <i>Oncology Letters</i> , 2021, 21, 185.	1.8	4
27	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.6	96
28	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 153-190.	2.8	99
29	Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial " SENTIX. <i>Gynecologic Oncology</i> , 2021, 160, 729-734.	1.4	8
30	Rationale for the avoidance of parametrectomy and systematic lymphadenectomy in patients with early stages of neuroendocrine cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 502-503.	2.5	1
31	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 609-619.	10.7	186
32	Are we better off using multiple endometriosis classifications in imaging and surgery than settle for one universal less than perfect protocol? Review of staging systems in ultrasound, magnetic resonance and surgery. <i>Journal of Obstetrics and Gynaecology</i> , 2021, , 1-7.	0.9	3
33	SIENDO/ENGOT-EN5/COG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5610-TPS5610.	1.6	6
34	Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5517-5517.	1.6	3
35	Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients. <i>Cancers</i> , 2021, 13, 2360.	3.7	15
36	<sc>ESGO</sc>/<sc>ISUOG</sc>/<sc>IOTA</sc>/<sc>ESGE</sc> Consensus Statement on preoperative diagnosis of ovarian tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 148-168.	1.7	42

#	ARTICLE	IF	CITATIONS
37	Terms, definitions and measurements to describe sonographic features of lymph nodes: consensus opinion from the Vulvar International Tumor Analysis (<scp>VITA</scp>) group. Ultrasound in Obstetrics and Gynecology, 2021, 57, 861-879.	1.7	24
38	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 961-982.	2.5	54
39	Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators. International Journal of Gynecological Cancer, 2021, 31, 1212-1219.	2.5	8
40	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. Journal of Clinical Oncology, 2021, 39, 3623-3632.	1.6	69
41	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecologic Oncology, 2021, 162, 652-660.	1.4	17
42	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
43	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
44	744â€¦Terms and definitions to describe sonographic features of lymph nodes: consensus opinion from the vulvar international tumor analysis (VITA) group. , 2021, , .		0
45	960â€¦The annual recurrence risk model for tailored surveillance strategy in cervical cancer patients. , 2021, , .		0
46	The annual recurrence risk model for tailored surveillance strategy inÂpatients with cervical cancer. European Journal of Cancer, 2021, 158, 111-122.	2.8	21
47	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529.	2.5	13
48	Validation of ultrasound strategies to assess tumor extension and to predict highâ€risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)â€4 cohort. Ultrasound in Obstetrics and Gynecology, 2020, 55, 115-124.	1.7	26
49	Final results from GCIG/ENGOT/AGOâ€OVAR 12, a randomised placeboâ€controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer, 2020, 146, 439-448.	5.1	40
50	Imaging in gynecological disease (19): clinical and ultrasound features of extragastrointestinal stromal tumors (<scp>eGIST</scp>). Ultrasound in Obstetrics and Gynecology, 2020, 56, 749-758.	1.7	8
51	Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX) Tj ETQq1 1 0z34314 r9BT /Over	2.8	14
52	Application of International Deep Endometriosis Analysis (IDEA) group consensus in preoperative ultrasound and magnetic resonance imaging of deep pelvic endometriosis. Ultrasound in Obstetrics and Gynecology, 2020, 56, 115-116.	1.7	5
53	Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer. Archives of Pathology and Laboratory Medicine, 2020, 144, 1011-1020.	2.5	10
54	Early Learning Curve in the Assessment of Deep Pelvic Endometriosis for Ultrasound and Magnetic Resonance Imaging. BioMed Research International, 2020, 2020, 1-7.	1.9	10

#	ARTICLE	IF	CITATIONS
55	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 2002-2007.	2.5	135
56	DNA methylation signatures to predict the cervicovaginal microbiome status. <i>Clinical Epigenetics</i> , 2020, 12, 180.	4.1	3
57	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) Tj ETQq1 1 0.784314 rgBT /Over 1627-1632.	2.5	16
58	Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. <i>European Journal of Cancer</i> , 2020, 137, 69-80.	2.8	56
59	SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1269-1277.	2.5	169
60	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	1.6	82
61	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824.	2.5	7
62	Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). <i>Cancers</i> , 2020, 12, 1115.	3.7	4
63	Management of pregnancy after fertility-sparing surgery for cervical cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 830-838.	2.8	8
64	Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study. <i>Cancers</i> , 2020, 12, 1438.	3.7	16
65	Diagnostic Accuracy of Ultrasound and MRI in the Mapping of Deep Pelvic Endometriosis Using the International Deep Endometriosis Analysis (IDEA) Consensus. <i>BioMed Research International</i> , 2020, 1-11.	1.9	34
66	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1164-1174.	1.6	194
67	ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 879-885.	1.7	23
68	European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 3-14.	2.5	39
69	Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues. <i>Scientific Reports</i> , 2020, 10, 6958.	3.3	5
70	Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 15-15.	2.5	45
71	Impact of sentinel lymph node frozen section evaluation to avoid combined treatment in early-stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 744-748.	2.5	9
72	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 6057-6057.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Management of patients with intermediate-risk early stage cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e54.	2.2	6
74	Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22½cases. <i>Oncology Letters</i> , 2019, 17, 2207-2214.	1.8	12
75	Laterally extended endopelvic resection with external iliac vessels resection and crossover ileofemoral bypass. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1338-1338.	2.5	2
76	Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. <i>Lancet Oncology</i> , The, 2019, 20, 1171-1182.	10.7	108
77	The association among cervical, anal, and oral HPV infections in high-risk and low-risk women. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology: X</i> , 2019, 4, 100061.	1.1	9
78	Modified rectus abdominis myoperitoneal flap for pelvic floor reconstruction. <i>Gynecologic Oncology</i> , 2019, 153, 463-464.	1.4	1
79	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 60-67.	2.5	43
80	Revised FIGO staging for carcinoma of the cervix uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 129-135.	2.3	612
81	Oncological outcome of surgical management in patients with recurrent uterine cancer—a multicenter retrospective cohort study—CEEGOG EX01 Trial. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 711-720.	2.5	7
82	ESMO—ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	1.2	665
83	Ultrasound characteristics of a symptomatic and asymptomatic lymphocele after pelvic and/or paraaortic lymphadenectomy. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 266-272.	1.3	7
84	Letter to the editor, Reply to: Cecile Colpaert et al.: Ultrastaging of sentinel lymph nodes in gynecological cancer: Repeating the story of breast cancer?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 94-95.	0.6	2
85	A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX). <i>International Journal of Gynecological Cancer</i> , 2019, 29, 212-215.	2.5	58
86	International radical trachelectomy assessment: IRTA study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 635-638.	2.5	35
87	Laterally Extended Pelvic Resection for Gynaecological Malignancies: A Multicentric Experience with Out-of-the-Box Surgery. <i>Annals of Surgical Oncology</i> , 2019, 26, 523-530.	1.5	24
88	Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. <i>Gynecologic Oncology</i> , 2019, 152, 202-207.	1.4	81
89	P18—Tumor free distance is the best predictive marker in patients with early-stage cervical cancer treated by primary surgery. , 2019, , .		0
90	A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. <i>Gynecologic Oncology</i> , 2018, 149, 140-145.	1.4	9

#	ARTICLE	IF	CITATIONS
91	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	27.6	129
92	SLN biopsy in cervical cancer patients with tumors larger than 2 cm and 4 cm. <i>Gynecologic Oncology</i> , 2018, 148, 456-460.	1.4	25
93	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 404-416.	0.6	241
94	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 641-655.	2.5	336
95	Are patients and physicians willing to accept less-radical procedures for cervical cancer?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e50.	2.2	1
96	ESGO Survey on Current Practice in the Management of Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1226-1231.	2.5	34
97	What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. <i>BMJ Open</i> , 2018, 8, e023789.	1.9	13
98	Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy" A retrospective cohort study and review of the literature. <i>Gynecologic Oncology</i> , 2018, 151, 438-443.	1.4	46
99	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	1.4	44
100	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 919-936.	2.8	127
101	Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5509-5509.	1.6	5
102	Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17515-e17515.	1.6	4
103	A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5601-TPS5601.	1.6	1
104	Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 263-274.	1.7	33
105	Pelvic floor reconstruction by modified rectus abdominis myoperitoneal (MRAM) flap after pelvic exenterations. <i>Gynecologic Oncology</i> , 2017, 144, 558-563.	1.4	20
106	The association of enchondromatosis with malignant transformed chondrosarcoma and ovarian juvenile granulosa cell tumor (Ollier disease). <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2017, 56, 253-257.	1.3	21
107	Utility and Actual Use of European and Spanish Guidelines on the Management of Endometrial Cancer Among Gynecologic Oncologists in Spain. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1293-1297.	2.5	2
108	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2720-2726.	1.5	44

#	ARTICLE	IF	CITATIONS
109	Sensitivity of Follow-Up Methods in Patients After Fertility-Sparing Surgery for Cervical Cancers. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 147-153.	2.5	8
110	Believable or not believable MRAM. <i>Gynecologic Oncology Reports</i> , 2017, 22, 111-112.	0.6	1
111	2017 Update on the Querleuâ€™Morrow Classification of Radical Hysterectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3406-3412.	1.5	162
112	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1534-1542.	2.5	121
113	Robotic and Advanced Laparoscopic Surgical Training in European Gynecological Oncology Trainees. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 375-381.	2.5	3
114	Accuracy of ultrasound in prediction of rectosigmoid infiltration in epithelial ovarian cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 533-538.	1.7	5
115	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017, 9, 115.	8.2	49
116	The Diagnostic Accuracy of Ultrasound in Assessment of Myometrial Invasion in Endometrial Cancer: Subjective Assessment versus Objective Techniques. <i>BioMed Research International</i> , 2017, 2017, 1-10.	1.9	25
117	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017, 9, 116.	8.2	122
118	European Surgical Education and Training in Gynecologic Oncology: The impact of an Accredited Fellowship. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 819-825.	2.5	6
119	Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5613-TPS5613.	1.6	4
120	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4345-4353.	1.6	68
121	Ovarian Cancer Screening There May Be Light at the End of the Tunnel?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 608-609.	2.5	1
122	Prospective Evaluation of Ultrasound Accuracy in the Detection of Pelvic Carcinomatosis in Patients with Ovarian Cancer. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2196-2202.	1.5	9
123	European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1354-1363.	2.5	104
124	Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. <i>Gynecologic Oncology</i> , 2016, 143, 83-86.	1.4	35
125	Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience. <i>Gynecologic Oncology</i> , 2016, 142, 401-404.	1.4	24
126	Serous tubal intraepithelial carcinoma (STIC) â€™ clinical impact and management. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1311-1321.	2.4	25

#	ARTICLE	IF	CITATIONS
127	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, 16-41.	1.2	862
128	Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions. <i>Pathology and Oncology Research</i> , 2016, 22, 523-530.	1.9	19
129	A Novel Perspective of Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2126-2127.	1.5	1
130	Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma. <i>Folia Biologica</i> , 2016, 62, 258-262.	0.6	3
131	The Work Place Educational Climate in Gynecological Oncology Fellowships Across Europe: The Impact of Accreditation. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 180-190.	2.5	19
132	Follow-up in Gynecological Malignancies: A State of Art. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1151-1164.	2.5	26
133	The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1094-1095.	2.5	1
134	European Network of Gynaecological Oncological Trial Groupsâ€™ Requirements for Trials Between Academic Groups and Industry Partnersâ€™ First Update 2015. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1328-1330.	2.5	22
135	Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion. <i>Neoplasma</i> , 2015, 62, 308-314.	1.6	26
136	Ultrasound in Gynecological Cancer: Is It Time for Re-evaluation of Its Uses?. <i>Current Oncology Reports</i> , 2015, 17, 28.	4.0	31
137	Expression of HNF-1 β in cervical carcinomas: an immunohistochemical study of 155 cases. <i>Diagnostic Pathology</i> , 2015, 10, 8.	2.0	13
138	PARP inhibitors in ovarian cancer. <i>British Journal of Cancer</i> , 2015, 113, S1-S2.	6.4	1
139	Oncological Outcomes of Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2015, 22, 3033-3040.	1.5	33
140	A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. <i>Gynecologic Oncology</i> , 2015, 137, 291-298.	1.4	98
141	Sentinel lymph node biopsy in the management of gynecologic cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 66-72.	2.0	69
142	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 87-97.	10.7	491
143	Radical Hysterectomy in Cervical Cancer. , 2015, , 353-365.		1
144	Lymphocele: prevalence and management in gynecological malignancies. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 307-317.	2.4	41

#	ARTICLE	IF	CITATIONS
145	Pelvic Lymphadenectomy Improves Survival in Patients With Cervical Cancer With Low-Volume Disease in the Sentinel Node: A Retrospective Multicenter Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 303-311.	2.5	30
146	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014, 6, 47.	8.2	53
147	Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008. <i>Cancer Epidemiology</i> , 2014, 38, 28-34.	1.9	17
148	Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. <i>Vaccine</i> , 2014, 32, 733-739.	3.8	49
149	The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. <i>Journal of Clinical Virology</i> , 2014, 59, 18-23.	3.1	39
150	Factors affecting sonographic preoperative local staging of endometrial cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 575-585.	1.7	42
151	DNA methylation markers for early detection of women's cancer: promise and challenges. <i>Epigenomics</i> , 2014, 6, 311-327.	2.1	76
152	A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial. <i>BMC Cancer</i> , 2014, 14, 635.	2.6	12
153	Bone quality assessment in type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2014, 25, 1969-1973.	3.1	151
154	The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1463-1477.	6.4	83
155	Factors influencing decisions about surgical treatment of cervical precancerous lesions. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 441-451.	2.4	3
156	A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5519-5519.	1.6	12
157	Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3134-TPS3134.	1.6	3
158	High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2013, 129, 384-388.	1.4	80
159	Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound – A European multicenter trial. <i>Gynecologic Oncology</i> , 2013, 128, 449-453.	1.4	115
160	Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation. <i>Annals of Surgical Oncology</i> , 2013, 20, 1348-1354.	1.5	64
161	Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 705-712.	1.7	23
162	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. <i>PLoS Medicine</i> , 2013, 10, e1001551.	8.4	135

#	ARTICLE	IF	CITATIONS
163	Umbilication Is a Strong Predictor of High-Grade Cervical Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, 303-307.	1.9	5
164	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1554-1561.	1.6	126
165	Hysteroscopic management of displaced levonorgestrel-releasing intrauterine system. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 1014-1018.	1.3	4
166	Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5516-5516.	1.6	5
167	Pelvic Lymphadenectomy. , 2013, , 83-87.		0
168	Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception. <i>Human Reproduction Update</i> , 2012, 18, 670-681.	10.8	12
169	The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. <i>PLoS Genetics</i> , 2012, 8, e1002517.	3.5	111
170	Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. <i>European Journal of Endocrinology</i> , 2012, 166, 1003-1011.	3.7	49
171	Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. <i>Oncologist</i> , 2012, 17, 1515-1533.	3.7	161
172	ESGO Statement on the Role of CA-125 Measurement in Follow-Up of Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 175-175.	2.5	6
173	An International Series on Abdominal Radical Trachelectomy: 101 Patients and 28 Pregnancies. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1251-1257.	2.5	98
174	Cancer Antigen 125: Lost to Follow-Up?. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 170-174.	2.5	12
175	Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. <i>Gynecologic Oncology</i> , 2012, 127, 462-466.	1.4	108
176	Ultrasonographic appearance of metastatic non-gynecological pelvic tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 39, 215-225.	1.7	15
177	Primary Synovial Sarcoma of the Uterus. <i>Pathology and Oncology Research</i> , 2012, 18, 529-533.	1.9	6
178	Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. <i>Cytopathology</i> , 2012, 23, 383-388.	0.7	7
179	Terminology and classification system of radical hysterectomy. <i>Gynecologic Oncology</i> , 2012, 124, 174-175.	1.4	0
180	Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2012, 124, 496-501.	1.4	174

#	ARTICLE	IF	CITATIONS
181	An international series on abdominal trachelectomy: 101 patients and 28 pregnancies. <i>Gynecologic Oncology</i> , 2012, 125, S4.	1.4	1
182	Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2012, 125, 303-306.	1.4	23
183	Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5001-5001.	1.6	50
184	Tubal ligation and the risk of ovarian cancer: review and meta-analysis. <i>Human Reproduction Update</i> , 2011, 17, 55-67.	10.8	230
185	Contraceptive behaviour of Czech and Romanian women: comparison of representative national samples. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 154, 163-166.	1.1	1
186	High-risk human papillomavirus DNA in paraaortic lymph nodes in advanced stages of cervical carcinoma. <i>Journal of Clinical Virology</i> , 2011, 50, 46-49.	3.1	5
187	Physiological Relevance of Pregnanolone Isomers and Their Polar Conjugates with Respect to the Gender, Menstrual Cycle and Pregnancy. , 2011, , .		0
188	Current Clinical Practice in Cytoreductive Surgery for Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	12
189	Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 289-295.	2.5	239
190	Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. <i>Oncology Reports</i> , 2011, 27, 318-24.	2.6	35
191	Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 559-563.	2.8	38
192	Abortions and Contraception Use Among Czech and Romanian Women: Comparison of Representative National Studies. <i>Journal of Sexual Medicine</i> , 2011, 8, 1083-1091.	0.6	3
193	New classification system of radical hysterectomy: Emphasis on a three-dimensional anatomic template for parametrial resection. <i>Gynecologic Oncology</i> , 2011, 122, 264-268.	1.4	112
194	OP24.07: Morphological and vascular ultrasound characteristics of pelvic masses of non-gynecological origin. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 127-127.	1.7	0
195	Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 652-655.	2.4	4
196	Oral contraceptives and risk of ovarian and breast cancers in <i>BRCA</i> mutation carriers: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1197-1207.	2.4	96
197	Local Control After Tailored Surgical Treatment of Early Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 690-698.	2.5	19
198	Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	9

#	ARTICLE	IF	CITATIONS
199	Human Papillomavirus DNA Presence in Pelvic Lymph Nodes in Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 126-132.	2.5	5
200	Factors Affecting Spontaneous Voiding Recovery After Radical Hysterectomy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 685-690.	2.5	23
201	Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 36, 767-772.	1.7	53
202	Uterine Tumors with Neuroectodermal Differentiation. A Report of 4 Cases. <i>Pathology and Oncology Research</i> , 2010, 16, 601-608.	1.9	13
203	Pelvic lymphadenectomy in cervical cancer—surgical anatomy and proposal for a new classification system. <i>Gynecologic Oncology</i> , 2010, 116, 33-37.	1.4	61
204	Late morbidity following nerve-sparing radical hysterectomy. <i>Gynecologic Oncology</i> , 2010, 116, 506-511.	1.4	54
205	Classification system for pelvic lymphadenectomy in cervical cancer. <i>Gynecologic Oncology</i> , 2010, 118, 94-95.	1.4	0
206	Late morbidity following nerve-sparing radical hysterectomy. <i>Gynecologic Oncology</i> , 2010, 119, 169-170.	1.4	0
207	Hormonal contraception and risk of cancer. <i>Human Reproduction Update</i> , 2010, 16, 631-650.	10.8	199
208	Sexual morbidity following radical hysterectomy for cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1037-1042.	2.4	30
209	Steroid metabolome in fetal and maternal body fluids in human late pregnancy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 122, 114-132.	2.5	66
210	Comparison of corticoid substitution versus combined oral contraception administration in the treatment of non-classic adrenal hyperplasia: A prospective study. <i>Gynecological Endocrinology</i> , 2009, 25, 398-402.	1.7	6
211	Impaired Glucose Metabolism in Women with Polycystic Ovary Syndrome. <i>Gynecologic and Obstetric Investigation</i> , 2009, 68, 186-190.	1.6	12
212	Surgical education and training in gynecologic oncology I: European perspective. <i>Gynecologic Oncology</i> , 2009, 114, S52-S55.	1.4	17
213	Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2009, 115, 46-50.	1.4	32
214	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. <i>International Journal of Cancer</i> , 2009, 125, 2214-2218.	5.1	59
215	OC23.01: Role of ultrasound in the referral of young patients with cervical cancer for fertility sparing surgery. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 43-43.	1.7	1
216	OC23.06: Adequacy and safety of ultrasound guided tru-cut biopsy in the management of abdomino-pelvic tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 44-45.	1.7	0

#	ARTICLE	IF	CITATIONS
217	OC23.07: Analysis of factors influencing tru-cut biopsy sample adequacy in management of abdomino-pelvic masses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 45-45.	1.7	0
218	OC27.01: Ultrasound diagnosis of extragenital abdominopelvic tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 52-53.	1.7	2
219	BMD and biochemical markers of bone turnover in adolescent girls on oral contraceptives with different estrogen content. <i>Bone</i> , 2009, 44, S259.	2.9	0
220	Abdominal Radical Trachelectomy in Fertility-Sparing Treatment of Early-Stage Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1407-1411.	2.5	71
221	High-Risk Human Papillomavirus DNA in the Primary Tumor, Sentinel, and Nonsentinel Pelvic Lymph Nodes in Patients With Early-Stage Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 703-707.	2.5	14
222	Primary pure large-cell neuroendocrine carcinoma of the ovary. <i>Pathology Research and Practice</i> , 2008, 204, 133-137.	2.3	27
223	OC129: Role of ultrasound in guiding of surgery radicality in cervical cancer management. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 285-285.	1.7	2
224	OC132: The role of ultrasound in prediction of optimal vs. suboptimal cytoreductive surgery in advanced ovarian cancers. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 286-286.	1.7	6
225	Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 833-837.	2.5	41
226	Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 766-772.	2.5	119
227	Update on abdominal radical trachelectomy. <i>Gynecologic Oncology</i> , 2008, 111, S111-S115.	1.4	44
228	Novel complex genomic rearrangement of the BRCA1 gene. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 637, 205-208.	1.0	5
229	Low-density lipoprotein receptor-related protein-5 C/T polymorphism in exon 18 is associated with C peptide and proinsulin levels in control women and patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2008, 90, 699-708.	1.0	1
230	Women's contraceptive practices and sexual behaviour in Europe. <i>European Journal of Contraception and Reproductive Health Care</i> , 2008, 13, 362-375.	1.5	73
231	Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women. <i>Gynecological Endocrinology</i> , 2008, 24, 154-157.	1.7	30
232	Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy. <i>Journal of Endocrinology</i> , 2007, 195, 67-78.	2.6	36
233	Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 639-44.	2.3	25
234	Role of D327N sex hormone-binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 104, 68-74.	2.5	21

#	ARTICLE	IF	CITATIONS
235	Circulating levels of pregnanolone isomers during the third trimester of human pregnancy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 105, 166-175.	2.5	56
236	OC229: Ultrasound-guided tru-cut biopsy in the management of advanced abdominopelvic tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 30, 437-437.	1.7	0
237	OC231: Transrectal ultrasound (TRUS) and MRI in staging of early cervical cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 30, 438-438.	1.7	0
238	Localization of the Sentinel Node of the Upper Outer Breast Quadrant in the Axillary Quadrants. <i>Annals of Surgical Oncology</i> , 2007, 14, 633-637.	1.5	11
239	Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20µg and Drospirenone 3mg. <i>Clinical Drug Investigation</i> , 2006, 26, 143-150.	2.2	19
240	OC167: Ultrasound-guided tru-cut biopsy in the diagnosis and management of inoperable pelvic tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2006, 28, 408-408.	1.7	0
241	Daniel R. Mishell, Jr., M.D., 75 years: A tribute to the master. <i>European Journal of Contraception and Reproductive Health Care</i> , 2006, 11, 59-59.	1.5	0
242	P08.01: Clear cell adenofibroma/fibrosarcoma of the ovary: ultrasound, macroscopic and histopathologic findings. A case report. <i>Ultrasound in Obstetrics and Gynecology</i> , 2005, 26, 426-426.	1.7	0
243	Reinstatement of Serum Pregnanolone Isomers and Progesterone During Alcohol Detoxification Therapy in Premenopausal Women. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 1010-1017.	2.4	5
244	Laparoscopic abdominal radical trachelectomy. <i>Gynecologic Oncology</i> , 2005, 97, 707-709.	1.4	61
245	Combined oral contraceptives in the treatment of polycystic ovary syndrome. <i>Human Reproduction Update</i> , 2005, 11, 277-291.	10.8	125
246	Metabolic syndrome in young Czech women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2005, 20, 3328-3332.	0.9	67
247	The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. <i>Human Reproduction</i> , 2005, 20, 180-184.	0.9	82
248	Insulin Sensitivity in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2942-2945.	3.6	115
249	Is insulin resistance an essential component of PCOS?: The influence of confounding factors. <i>Human Reproduction</i> , 2004, 19, 757-759.	0.9	39
250	Comparison of the Insulin Action Parameters from Hyperinsulinemic Clamps with Homeostasis Model Assessment and QUICKI Indexes in Subjects with Different Endocrine Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 135-141.	3.6	93
251	Polycystic Ovary Syndrome: Implications for Cardiovascular, Endometrial, and Breast Disease. , 2004, , 4-6.		0
252	Pregnancy outcome in women with PCOS and in controls matched by age and weight. <i>Human Reproduction</i> , 2003, 18, 1438-1441.	0.9	104

#	ARTICLE	IF	CITATIONS
253	Prediction of Insulin Sensitivity in Nonobese Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5821-5825.	3.6	41
254	Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. <i>Human Reproduction</i> , 2002, 17, 76-82.	0.9	44
255	Prediction of insulin sensitivity in non-obese women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2002, 78, S279.	1.0	0
256	Prevalence of apoptosis in endometriotic lesions. <i>Fertility and Sterility</i> , 2002, 78, S199-S200.	1.0	0
257	Neuroactive steroids, their precursors and polar conjugates during parturition and postpartum in maternal and umbilical blood: 3. 3β -hydroxy-5-ene steroids. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002, 82, 241-250.	2.5	14
258	Neuroactive steroids, their precursors and polar conjugates during parturition and postpartum in maternal blood: 2. Time profiles of pregnanolone isomers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 78, 51-57.	2.5	29
259	Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?. <i>Human Reproduction</i> , 2001, 16, 940-944.	0.9	40
260	The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2001, 144, 619-628.	3.7	73
261	Exploratory Biochemical Data Analysis: a Comparison of Two Sample Means and Diagnostic Displays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 244-55.	2.3	2
262	The role of androgens in determining acne severity in adult women. <i>British Journal of Dermatology</i> , 2000, 143, 399-404.	1.5	91
263	Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. <i>Human Reproduction</i> , 2000, 15, 785-789.	0.9	223
264	An analysis of the relationship between insulin resistance and the activity of steroid C17,20-lyase and 3β -hydroxysteroid dehydrogenase in ovaries and adrenals in women with polycystic ovary syndrome. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2000, 108, 455-462.	1.2	6
265	The best correlation of the new index of hyperandrogenism with the grade of increased body hair. <i>European Journal of Endocrinology</i> , 2000, 143, 405-408.	3.7	24
266	Neuroactive steroids, their precursors, and polar conjugates during parturition and postpartum in maternal and umbilical blood: 1. identification and simultaneous determination of pregnanolone isomers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 75, 237-244.	2.5	38
267	Multiple ovarian biopsy in the treatment of women with polycystic ovary syndrome (PCOS). <i>Clinical and Experimental Obstetrics and Gynecology</i> , 2000, 27, 194-6.	0.2	4